{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:06:06Z","timestamp":1793048766983,"version":"4.5.0"},"reference-count":95,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2013,2,21]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Mast cell leukemia (MCL) is a very rare form of aggressive systemic mastocytosis accounting for &lt; 1% of all mastocytosis. It may appear de novo or secondary to previous mastocytosis and shares more clinicopathologic aspects with systemic mastocytosis than with acute myeloid leukemia. Symptoms of mast cell activation\u2014involvement of the liver, spleen, peritoneum, bones, and marrow\u2014are frequent. Diagnosis is based on the presence of \u2265 20% atypical mast cells in the marrow or \u2265 10% in the blood; however, an aleukemic variant is frequently encountered in which the number of circulating mast cells is &lt; 10%. The common phenotypic features of pathologic mast cells encountered in most forms of mastocytosis are unreliable in MCL. Unexpectedly, non-KIT D816V mutations are frequent and therefore, complete gene sequencing is necessary. Therapy usually fails and the median survival time is &lt; 6 months. The role of combination therapies and bone marrow transplantation needs further investigation.<\/jats:p>","DOI":"10.1182\/blood-2012-07-442400","type":"journal-article","created":{"date-parts":[[2012,12,16]],"date-time":"2012-12-16T01:46:10Z","timestamp":1355622370000},"page":"1285-1295","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":159,"title":["Mast cell leukemia"],"prefix":"10.1182","volume":"121","author":[{"given":"Sophie","family":"Georgin-Lavialle","sequence":"first","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence des Mastocytoses, Facult\u00e9 de M\u00e9decine et Assistance Publique\u2013Hopitaux de Paris (AP-HP) Necker-Enfants Malades, Paris, France;"},{"name":"Laboratoire d'Hematologie Biologique, H\u00f4pital Necker-Enfants Malades, AP-HP, Paris, France;"},{"name":"Service de M\u00e9decine Interne, H\u00f4pital Tenon, AP-HP, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovic","family":"Lhermitte","sequence":"additional","affiliation":[{"name":"Laboratoire d'Hematologie Biologique, H\u00f4pital Necker-Enfants Malades, AP-HP, Paris, France;"},{"name":"UMR CNRS 8147, Universit\u00e9 Paris Descartes, Paris Sorbonne Cit\u00e9, Facult\u00e9 de M\u00e9decine, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrice","family":"Dubreuil","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence des Mastocytoses, Facult\u00e9 de M\u00e9decine et Assistance Publique\u2013Hopitaux de Paris (AP-HP) Necker-Enfants Malades, Paris, France;"},{"name":"Inserm, U1068, Centre de Recherche en Canc\u00e9rologie de Marseille (CRCM), Signaling, Hematopoiesis and Mechanism of Oncogenesis, Institut Paoli-Calmettes, Marseille; Aix-Marseille Universit\u00e9; CNRS, UMR7258, Marseille, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Olivia","family":"Chandesris","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence des Mastocytoses, Facult\u00e9 de M\u00e9decine et Assistance Publique\u2013Hopitaux de Paris (AP-HP) Necker-Enfants Malades, Paris, France;"},{"name":"Service d'H\u00e9matologie Adultes, Universit\u00e9 Paris Descartes, Paris Sorbonne Cit\u00e9, Facult\u00e9 de M\u00e9decine et AP-HP Necker-Enfants Malades, Paris, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence des Mastocytoses, Facult\u00e9 de M\u00e9decine et Assistance Publique\u2013Hopitaux de Paris (AP-HP) Necker-Enfants Malades, Paris, France;"},{"name":"UMR CNRS 8147, Universit\u00e9 Paris Descartes, Paris Sorbonne Cit\u00e9, Facult\u00e9 de M\u00e9decine, Paris, France;"},{"name":"Service d'H\u00e9matologie Adultes, Universit\u00e9 Paris Descartes, Paris Sorbonne Cit\u00e9, Facult\u00e9 de M\u00e9decine et AP-HP Necker-Enfants Malades, Paris, France;"},{"name":"Institut Imagine, AP-HP Necker-Enfants Malades, Paris, France; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gandhi","family":"Damaj","sequence":"additional","affiliation":[{"name":"Centre de R\u00e9f\u00e9rence des Mastocytoses, Facult\u00e9 de M\u00e9decine et Assistance Publique\u2013Hopitaux de Paris (AP-HP) Necker-Enfants Malades, Paris, France;"},{"name":"UMR CNRS 8147, Universit\u00e9 Paris Descartes, Paris Sorbonne Cit\u00e9, Facult\u00e9 de M\u00e9decine, Paris, France;"},{"name":"Service d'H\u00e9matologie, Centre Hospitalier Universitaire, H\u00f4pital Sud, Amiens, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111910462355600_B1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"6","key":"2019111910462355600_B2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/j.1365-2362.2007.01807.x","article-title":"Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria.","volume":"37","author":"Valent","year":"2007","journal-title":"Eur J Clin Invest"},{"issue":"5","key":"2019111910462355600_B3","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1046\/j.1365-2141.2003.04575.x","article-title":"Diagnosis and treatment of systemic mastocytosis: state of the art.","volume":"122","author":"Valent","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111910462355600_B4","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00062752-200401000-00009","article-title":"Clinical, genetic, and therapeutic insights into systemic mast cell disease.","volume":"11","author":"Tefferi","year":"2004","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"2019111910462355600_B5","first-page":"197","article-title":"Systemic mastocytosis: current concepts and treatment advances.","volume":"3","author":"Tefferi","year":"2004","journal-title":"Curr Hematol Rep"},{"issue":"23","key":"2019111910462355600_B6","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1182\/blood-2009-02-205237","article-title":"Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.","volume":"113","author":"Lim","year":"2009","journal-title":"Blood"},{"issue":"6","key":"2019111910462355600_B7","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00277-007-0430-3","article-title":"Mast cell leukemia: a report of ten cases.","volume":"87","author":"Valentini","year":"2008","journal-title":"Ann Hematol"},{"issue":"5","key":"2019111910462355600_B8","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/leu.2011.293","article-title":"An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis.","volume":"26","author":"Teodosio","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"2019111910462355600_B9","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1080\/10428190412331272695","article-title":"Aleukemic mast cell leukemia with abnormal immunophenotype and c-kit mutation D816V.","volume":"45","author":"Noack","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"2019111910462355600_B10","first-page":"437","article-title":"Uber Mastzellenleukamien.","volume":"87","author":"Joachim","year":"1906","journal-title":"Deutsches Archives fur Klinische Medizin"},{"issue":"1","key":"2019111910462355600_B11","first-page":"159","article-title":"A case of malignant mastocytosis with circulating mast cell precursors: biologic and phenotypic characterization of the malignant clone.","volume":"10","author":"Baghestanian","year":"1996","journal-title":"Leukemia"},{"issue":"1","key":"2019111910462355600_B12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1365-2141.1980.tb03805.x","article-title":"Cytobiological and clinical aspects of tissue mast cell leukaemia.","volume":"45","author":"Coser","year":"1980","journal-title":"Br J Haematol"},{"issue":"2","key":"2019111910462355600_B13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2141.1986.tb04133.x","article-title":"Mast cell leukaemia: evidence for bone marrow origin of the pathological clone.","volume":"64","author":"Dalton","year":"1986","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111910462355600_B14","first-page":"319","article-title":"[Acute mast-cell leukemia. Cytochemical and ultrastructural study, about a particular case (author's transl)].","volume":"15","author":"Daniel","year":"1975","journal-title":"Nouv Rev Fr Hematol"},{"issue":"10","key":"2019111910462355600_B15","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.V12.10.869.869","article-title":"Mast cell leukemia? Malignant mastocytosis with leukemia-like manifestations.","volume":"12","author":"Efrati","year":"1957","journal-title":"Blood"},{"issue":"1","key":"2019111910462355600_B16","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1182\/blood.V13.1.70.70","article-title":"Tissue mast cell leukemia.","volume":"13","author":"Friedman","year":"1958","journal-title":"Blood"},{"issue":"1","key":"2019111910462355600_B17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S0002-9270(97)00042-7","article-title":"Systemic mastocytosis: a rare cause of noncirrhotic portal hypertension simulating autoimmune cholangitis\u2013report of four cases.","volume":"93","author":"Kyriakou","year":"1998","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"2019111910462355600_B18","first-page":"621","article-title":"[Acute mast cell leukemia disclosed by vasomotor flushing].","volume":"124","author":"Le Cam","year":"1997","journal-title":"Ann Dermatol Venereol"},{"issue":"2","key":"2019111910462355600_B19","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0002-9343(62)90292-9","article-title":"Systemic mast cell disease: a review and report of three cases.","volume":"32","author":"Szweda","year":"1962","journal-title":"Am J Med"},{"issue":"12","key":"2019111910462355600_B20","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0025-6196(12)62636-6","article-title":"Mast cell leukemia: report of a case and review of the literature.","volume":"61","author":"Travis","year":"1986","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"2019111910462355600_B21","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0016-5085(88)80012-X","article-title":"Gastrointestinal dysfunction in systemic mastocytosis. A prospective study.","volume":"95","author":"Cherner","year":"1988","journal-title":"Gastroenterology"},{"issue":"6","key":"2019111910462355600_B22","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0002-9343(89)80398-5","article-title":"Analysis of plasma histamine levels in patients with mast cell disorders.","volume":"87","author":"Friedman","year":"1989","journal-title":"Am J Med"},{"issue":"40","key":"2019111910462355600_B23","first-page":"686","article-title":"Mastocytosis: a disease of the hematopoietic stem cell.","volume":"105","author":"Horny","year":"2008","journal-title":"Dtsch Arztebl Int"},{"issue":"8","key":"2019111910462355600_B24","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/ajh.21713","article-title":"Myelomastocytic leukemia versus mast cell leukemia versus systemic mastocytosis associated with acute myeloid leukemia: a diagnostic challenge.","volume":"85","author":"Arredondo","year":"2010","journal-title":"Am J Hematol"},{"issue":"2","key":"2019111910462355600_B25","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000101711","article-title":"Mastocytosis: state of the art.","volume":"74","author":"Horny","year":"2007","journal-title":"Pathobiology"},{"issue":"5-6","key":"2019111910462355600_B26","first-page":"173","article-title":"Mast cell leukemia\u2013a rare form of myeloid leukemia.","volume":"114","author":"Valent","year":"2002","journal-title":"Wien Klin Wochenschr"},{"issue":"3","key":"2019111910462355600_B27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jaci.2009.10.020","article-title":"Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes.","volume":"125","author":"Teodosio","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"2019111910462355600_B28","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2006-04-015545","article-title":"KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients.","volume":"108","author":"Garcia-Montero","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111910462355600_B29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1600-0609.2012.01761.x","article-title":"Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.","volume":"89","author":"Georgin-Lavialle","year":"2012","journal-title":"Eur J Haematol"},{"issue":"6","key":"2019111910462355600_B30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-0609.2011.01598.x","article-title":"A case of mast cell leukaemia with exon 9 KIT mutation and good response to imatinib.","volume":"86","author":"Mital","year":"2011","journal-title":"Eur J Haematol"},{"issue":"8","key":"2019111910462355600_B31","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"2019111910462355600_B32","article-title":"Mast cell sarcoma, a rare and aggressive entity: report of 2 cases and review of the literature [published online ahead of print November 5, 2012].","author":"Georgin-Lavialle","journal-title":"J Clin Oncol"},{"issue":"6","key":"2019111910462355600_B33","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1038\/leu.2011.354","article-title":"Mast-cell leukemia exome sequencing reveals a mutation in the IgE mast-cell receptor beta chain and KIT V654A.","volume":"26","author":"Spector","year":"2012","journal-title":"Leukemia"},{"issue":"5","key":"2019111910462355600_B34","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1038\/leu.2009.37","article-title":"Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates.","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"2019111910462355600_B35","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1182\/blood-2011-12-397588","article-title":"In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells.","volume":"120","author":"Soucie","year":"2012","journal-title":"Blood"},{"issue":"5","key":"2019111910462355600_B36","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1525-1470.2011.01650.x","article-title":"Death from mast cell leukemia: a young patient with longstanding cutaneous mastocytosis evolving into fatal mast cell leukemia.","volume":"29","author":"Chantorn","year":"2012","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2019111910462355600_B37","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1542\/peds.19.6.1033","article-title":"Mast cell leukemia presenting as urticaria pigmentosa; report of a case.","volume":"19","author":"Waters","year":"1957","journal-title":"Pediatrics"},{"issue":"3","key":"2019111910462355600_B38","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1038\/jid.2009.281","article-title":"Pediatric mastocytosis is a clonal disease associated with D(816)V and other activating c-KIT mutations.","volume":"130","author":"Bodemer","year":"2010","journal-title":"J Invest Dermatol"},{"issue":"26","key":"2019111910462355600_B39","doi-asserted-by":"crossref","first-page":"5812","DOI":"10.1182\/blood-2010-08-292144","article-title":"How I treat patients with advanced systemic mastocytosis.","volume":"116","author":"Valent","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111910462355600_B40","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1056\/NEJM199202273260907","article-title":"Response to interferon alfa-2b in a patient with systemic mastocytosis.","volume":"326","author":"Kluin-Nelemans","year":"1992","journal-title":"N Engl J Med"},{"issue":"3","key":"2019111910462355600_B41","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha.","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br J Dermatol"},{"issue":"5-6","key":"2019111910462355600_B42","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3109\/10428199609054789","article-title":"Treatment of three patients with systemic mastocytosis with interferon alpha-2b.","volume":"22","author":"Worobec","year":"1996","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111910462355600_B43","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients.","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111910462355600_B44","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0145-2126(03)00259-5","article-title":"Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.","volume":"28","author":"Hauswirth","year":"2004","journal-title":"Leuk Res"},{"issue":"4","key":"2019111910462355600_B45","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1159\/000204898","article-title":"Anaphylactic-like syndrome in systemic mastocytosis treated with alpha-2-interferon.","volume":"85","author":"Pardini","year":"1991","journal-title":"Acta Haematol"},{"issue":"10","key":"2019111910462355600_B46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s00277-005-1057-x","article-title":"Cladribine therapy in a patient with an aleukemic subvariant of mast cell leukemia.","volume":"84","author":"Penack","year":"2005","journal-title":"Ann Hematol"},{"issue":"7","key":"2019111910462355600_B47","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood.V94.7.2333.419k30_2333_2342","article-title":"Demonstration that human mast cells arise from a progenitor cell population that is CD34(+), c-kit(+), and expresses aminopeptidase N (CD13).","volume":"94","author":"Kirshenbaum","year":"1999","journal-title":"Blood"},{"issue":"5","key":"2019111910462355600_B48","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1172\/JCI114865","article-title":"Potent toxicity of 2-chlorodeoxyadenosine toward human monocytes in vitro and in vivo. A novel approach to immunosuppressive therapy.","volume":"86","author":"Carrera","year":"1990","journal-title":"J Clin Invest"},{"issue":"2","key":"2019111910462355600_B49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0145-2126(03)00185-1","article-title":"Treatment of systemic mast cell disease with 2-chlorodeoxyadenosine.","volume":"28","author":"Pardanani","year":"2004","journal-title":"Leuk Res"},{"issue":"13","key":"2019111910462355600_B50","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1182\/blood-2003-05-1699","article-title":"Cladribine therapy for systemic mastocytosis.","volume":"102","author":"Kluin-Nelemans","year":"2003","journal-title":"Blood"},{"issue":"26","key":"2019111910462355600_B51","doi-asserted-by":"crossref","first-page":"5342","DOI":"10.1182\/blood-2008-08-175190","article-title":"Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs.","volume":"114","author":"Aichberger","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111910462355600_B52","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","article-title":"Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.","volume":"108","author":"Gabillot-Carre","year":"2006","journal-title":"Blood"},{"issue":"2","key":"2019111910462355600_B53","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1182\/blood-2005-07-3022","article-title":"PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects.","volume":"107","author":"Gleixner","year":"2006","journal-title":"Blood"},{"issue":"4","key":"2019111910462355600_B54","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1172\/JCI116761","article-title":"Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product.","volume":"92","author":"Furitsu","year":"1993","journal-title":"J Clin Invest"},{"issue":"4","key":"2019111910462355600_B55","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1073\/pnas.96.4.1609","article-title":"Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis.","volume":"96","author":"Longley","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"2019111910462355600_B56","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm.","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"issue":"5","key":"2019111910462355600_B57","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"issue":"4","key":"2019111910462355600_B58","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/labinvest.3700524","article-title":"Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation.","volume":"87","author":"Nakagomi","year":"2007","journal-title":"Lab Invest"},{"issue":"7","key":"2019111910462355600_B59","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/S0145-2126(01)00028-5","article-title":"Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy.","volume":"25","author":"Longley","year":"2001","journal-title":"Leuk Res"},{"issue":"5","key":"2019111910462355600_B60","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"issue":"12","key":"2019111910462355600_B61","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.","volume":"1","author":"Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2019111910462355600_B62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3324\/haematol.11836","article-title":"Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.","volume":"93","author":"Lahortiga","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2019111910462355600_B63","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/cncr.21996","article-title":"Imatinib mesylate in the treatment of systemic mastocytosis: a phase II trial.","volume":"107","author":"Droogendijk","year":"2006","journal-title":"Cancer"},{"issue":"10","key":"2019111910462355600_B64","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1517\/14712598.7.10.1597","article-title":"Imatinib mesylate in the treatment of hematologic malignancies.","volume":"7","author":"Piccaluga","year":"2007","journal-title":"Expert Opin Biol Ther"},{"issue":"9383","key":"2019111910462355600_B65","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease.","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"issue":"12","key":"2019111910462355600_B66","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.21894","article-title":"Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.","volume":"85","author":"Paul","year":"2010","journal-title":"Am J Hematol"},{"issue":"1","key":"2019111910462355600_B67","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis.","volume":"108","author":"Shah","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111910462355600_B68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.CAN-05-2050","article-title":"Dasatinib (BMS-354825), a dual SRC\/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.","volume":"66","author":"Schittenhelm","year":"2006","journal-title":"Cancer Res"},{"issue":"12","key":"2019111910462355600_B69","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1158\/1078-0432.CCR-08-0366","article-title":"Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2019111910462355600_B70","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1600-0609.2008.01048.x","article-title":"Dasatinib therapy for systemic mastocytosis: four cases.","volume":"80","author":"Purtill","year":"2008","journal-title":"Eur J Haematol"},{"issue":"6","key":"2019111910462355600_B71","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1182\/blood-2007-08-104372","article-title":"The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils.","volume":"111","author":"Kneidinger","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111910462355600_B72","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1111\/j.1365-2362.2008.02036.x","article-title":"Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis.","volume":"38","author":"Aichberger","year":"2008","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"2019111910462355600_B73","doi-asserted-by":"crossref","first-page":"2865","DOI":"10.1182\/blood-2005-04-1568","article-title":"Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation.","volume":"106","author":"Gotlib","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2019111910462355600_B74","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1182\/blood-2004-12-4617","article-title":"Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.","volume":"106","author":"Growney","year":"2005","journal-title":"Blood"},{"issue":"21","key":"2019111910462355600_B75","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V120.21.799.799","article-title":"KIT inhibitor midostaurin in patients with advanced systemic mastocytosis: results of a planned interim analysis of the global CPKC412D2201 trial.","volume":"120","author":"Gotlib","year":"2012","journal-title":"Blood"},{"issue":"3","key":"2019111910462355600_B76","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/1042819021000046976","article-title":"Induction of apoptosis in the human mast cell leukemia cell line HMC-1 by various antineoplastic drugs.","volume":"44","author":"Samorapoompichit","year":"2003","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2019111910462355600_B77","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1136\/jcp.2006.040857","article-title":"Mast-cell sarcoma of the tibia.","volume":"60","author":"Brcic","year":"2007","journal-title":"J Clin Pathol"},{"issue":"22","key":"2019111910462355600_B78","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.2169\/internalmedicine.48.2294","article-title":"Successful treatment of KIT D816V-positive, imatinib-resistant systemic mastocytosis with interferon-alpha.","volume":"48","author":"Yoshida","year":"2009","journal-title":"Intern Med"},{"issue":"6","key":"2019111910462355600_B79","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1053\/apmr.2002.32308","article-title":"Low back pain and myalgias in acute and relapsed mast cell leukemia: a case report.","volume":"83","author":"Lin","year":"2002","journal-title":"Arch Phys Med Rehabil"},{"issue":"6","key":"2019111910462355600_B80","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/sj.bmt.1704627","article-title":"Evidence for a graft-versus-mast-cell effect after allogeneic bone marrow transplantation.","volume":"34","author":"Spyridonidis","year":"2004","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"2019111910462355600_B81","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/sj.bmt.1705245","article-title":"A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis.","volume":"37","author":"Nakamura","year":"2006","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2019111910462355600_B82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/sj.bmt.1704098","article-title":"Rapid engraftment of mast cells of donor origin in a case of acute myeloid leukemia with mast cell leukemia after allogeneic stem cell transplantation.","volume":"32","author":"Chen","year":"2003","journal-title":"Bone Marrow Transplant"},{"issue":"82","key":"2019111910462355600_B83","first-page":"1765","article-title":"Examination of a new hematodermia; mastocytosis.","volume":"59","author":"Hissard","year":"1951","journal-title":"Presse Med"},{"key":"2019111910462355600_B84","first-page":"1046","article-title":"Mast cell reticulosis (tissular basophiloma) with histamine flushes and development into tissular basophilic leukemia.","volume":"89","author":"Brinkmann","year":"1959","journal-title":"Schweiz Med Wochenschr"},{"key":"2019111910462355600_B85","doi-asserted-by":"crossref","first-page":"887","DOI":"10.7326\/0003-4819-59-6-887","article-title":"Systemic mast cell disease.","volume":"59","author":"Mutter","year":"1963","journal-title":"Ann Intern Med"},{"issue":"2","key":"2019111910462355600_B86","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1002\/1097-0142(197602)37:2<693::AID-CNCR2820370213>3.0.CO;2-X","article-title":"An approach to immunotherapy using antibody to IgE in mast cell leukemia.","volume":"37","author":"Clancy","year":"1976","journal-title":"Cancer"},{"issue":"9","key":"2019111910462355600_B87","first-page":"1137","article-title":"[A case of mastocytoma with leukemic manifestation of its immature form in the terminal stage (author's transl)].","volume":"20","author":"Kimura","year":"1979","journal-title":"Rinsho Ketsueki"},{"issue":"6","key":"2019111910462355600_B88","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/jcp.39.6.596","article-title":"Mast cell sarcoma of the larynx.","volume":"39","author":"Horny","year":"1986","journal-title":"J Clin Pathol"},{"issue":"2","key":"2019111910462355600_B89","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/(SICI)1097-0320(19970415)30:2<98::AID-CYTO4>3.0.CO;2-9","article-title":"Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia.","volume":"30","author":"Escribano","year":"1997","journal-title":"Cytometry"},{"issue":"4","key":"2019111910462355600_B90","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archinte.159.4.401","article-title":"Mastocytosis: diverse presentations and outcomes.","volume":"159","author":"Pauls","year":"1999","journal-title":"Arch Intern Med"},{"issue":"5-6","key":"2019111910462355600_B91","first-page":"222","article-title":"[Aleukemic mast cell leukemia (formerly: \u201cmalignant mastocytosis\u201d): an extremely rare form of leukemia. A case report and simultaneously a contribution to revised classification of mastocytosis].","volume":"114","author":"Horny","year":"2002","journal-title":"Wien Klin Wochenschr"},{"key":"2019111910462355600_B92","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev.med.55.091902.103822","article-title":"Systemic mastocytosis.","volume":"55","author":"Akin","year":"2004","journal-title":"Annu Rev Med"},{"issue":"12","key":"2019111910462355600_B93","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.3324\/haematol.11996","article-title":"Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens.","volume":"92","author":"Krauth","year":"2007","journal-title":"Haematologica"},{"issue":"11","key":"2019111910462355600_B94","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1440-1827.2009.02451.x","article-title":"Mast cell leukemia with rapidly progressing portal hypertension.","volume":"59","author":"Yoshida","year":"2009","journal-title":"Pathol Int"},{"key":"2019111910462355600_B95","first-page":"517546","article-title":"Mast cell leukaemia: c-KIT mutations are not always positive.","author":"Joris","year":"2012","journal-title":"Case Report Hematol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/8\/1285\/1369433\/zh800813001285.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/121\/8\/1285\/1369433\/zh800813001285.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T13:39:37Z","timestamp":1643895577000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/121\/8\/1285\/138842\/Mast-cell-leukemia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,21]]},"references-count":95,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,2,21]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-07-442400","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,2,21]]}}}